Navigation Links
Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
Date:5/6/2008

ng surgery, Cethrin is delivered by a single application to the injured region of the spinal cord. Cethrin has been designated as an Orphan Drug by the FDA.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's focus is reflected in several important initiatives. Cethrin, a recombinant- protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technol
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Fla. , Dec. 19, 2014 Breckenridge ... a multi-product agreement with MSN Laboratories Pvt. Ltd. ( ... MSN expect to commercialize several new ANDAs.  Under the ... supply the products exclusively to Breckenridge for the U.S. ... under its label.  Breckenridge and MSN have agreed to ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 ... ;  Sorrento), an oncology company developing new treatments ... a privately-held immuno-oncology company developing proprietary Neukoplast ® ... therapy, announced today that the companies have entered ... generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... the United States will increase ... Growth will be primarily driven by expansion in the ... direct energy devices will be increasingly adopted due to ... launched. Other key findings from Decision Resources ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
... 10, 2012 Cyberonics, Inc. (NASDAQ: CYBX ), ... management of epilepsy, today announced it will participate in the ... 2012, in New York. Greg Browne, Senior Vice ... Eastern Time.  A live audio webcast of the presentation can ...
... Feb. 10, 2012  Zacks highlights commentary from People and Picks ... http://photos.prnewswire.com/prnh/20101027/ZIRLOGO ) For more Voice of the People, ... Market Percolates, Doubters Wait They,re coming ... course the troll community. They,re telling you the market is ...
Cached Medicine Technology:Zacks' Voice of the People highlights opportunities with Walgreen, Occidental Petroleum and Brown & Brown 2Zacks' Voice of the People highlights opportunities with Walgreen, Occidental Petroleum and Brown & Brown 3
(Date:12/20/2014)... 20, 2014 (HealthDay News) -- The holidays can be ... contend with fresh trees, scented candles and other allergy ... the decorations that have been packed away in dank ... allergy and asthma patients," Dr. Rachna Shah, an affiliate ... Medicine, said in Loyola news release. Shah, who ...
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, ... of a decade. They’ve treated over 40,000 patients while ... healthcare alternative to the Paramus area. , For ... to their staff of top-notch board certified physicians: Christine Milosis ... These new doctors will work tirelessly to carry out ...
(Date:12/20/2014)... December 20, 2014 As Risperdal ... forward in U.S. courts, Bernstein Liebhard LLP notes ... that children treated with the medication may experience ... breast development and lactation. The study, which appears ... and adolescents who began treatment with risperidone, an ...
(Date:12/20/2014)... 2014 The aftermath of the November 24th ... not only in Hollywood, but worldwide. As reported ... ripples of that attack are starting a finger-pointing game which ... But they are not the only ones affected, regular ... for some embarrassing times ahead, agents and lawyers could be ...
(Date:12/20/2014)... California (PRWEB) December 20, 2014 Developers ... the release of a new plugin for Final Cut ... Studios. , “TranSlice Volume 5 allows users to create ... draw it.” Said Christina Austin, CEO of Pixel Film ... level of professionalism while maintaining an easy to use ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... Law Offers Safe Option for Unwanted Babies, Prevents Abandonment ... of,Public Welfare Secretary Estelle B. Richman today reminded expectant,parents ... allows,them to confidentially turn over unwanted infants, up to ... abandonment., On Nov. 10, a newborn baby boy ...
... the implementation,of its best management practices (BMPs), the ... the environment, the ADA told Congress today., ... had a very positive,impact," said Dr. J. Rodway ... House Oversight and Government Reform Committee,s,domestic policy panel. ...
... say , WEDNESDAY, Nov. 14 (HealthDay News) -- U.S. scientists ... in cancer cells. , They found that genes in cancer ... structures called nucleosomes within the cells. , "The study shows ... in cancer cells. It identifies what the target looks like, ...
... U.S. Food and Drug Administration, an international coalition of ... stem the flood of dangerous drugs reaching American consumers ... methods when those alternatives exist. , Petition signatories ... to accept the recently proposed settlement with Merck because ...
... Chili,s Grill & Bar, other partners and donors ... researchers into the new National,Pediatric Brain Tumor Consortium ... practice learning in,translational research for exceptional patient care, ... Children,s,Research Hospital(R) and Chili,s Grill & Bar(R) celebrated ...
... Pain from Peripheral Arterial Disease is Caused,by Smoking, ... are well,aware of the risk of cancer from ... the body,s vascular system. Smoking damages the,blood vessels ... diseases including,peripheral arterial disease (PAD), stroke, heart attack, ...
Cached Medicine News:Health News:Pa. Department of Public Welfare Reminds New Parents About 'Safe Haven' Law 2Health News:ADA Outlines Successful Environmental Efforts 2Health News:FDA petition would protect public from dangerous drugs 2Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 2Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 3Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 4Health News:A New Reason to Quit for the Great American Smokeout 2
... mg/kg sulfate (SO 4 ) ≤ 1000 mg/kg Cation ... Co ≤ 5 mg/kg Cr ≤ 10 mg/kg Cu ... 5 mg/kg Mg ≤ 5 mg/kg Mn ≤ 5 ... Pb ≤ 5 mg/kg Zn ≤ 5 mg/kg Special ...
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
Inquire...
Medicine Products: